Equasens Société anonyme (EQS) H1 2025 TU earnings summary

Executive summary

• H1 2025 revenue reached €116.0m, up 7.4% reported and 6.4% like-for-like year-over-year.

• Growth driven by strong performances in Pharmagest, Axigate Link, e-Connect, and Medical Solutions divisions.

• Strategic acquisitions and new product launches contributed to momentum across all business lines.

Financial highlights

• Q1 2025 revenue: €57.0m (+6.9%); Q2 2025 revenue: €58.9m (+7.8%) compared to prior year.

• Configurations and hardware sales rose 9.9% to €47.1m; maintenance and subscriptions up 5.5% to €51.4m.

• Software and services revenue increased 6.4% to €17.4m year-over-year.

Outlook and guidance

• Positive commercial momentum expected to continue in H2 2025, with further growth anticipated.

• Integration of DIS and ResUrgences to enhance Axigate Link Division performance from Q3 2025.

• Ongoing monitoring of public authority decisions on health insurance compensation, which could impact pharmacy economics.